In contrast, in the CheckMate-451 study, first-line chemotherapy followed by maintenance with anti-PD-1 agent (nivolumab) failed to prolonged OS in ES-SCLC [13]. The gene discussed is PDCD1; the disease is small cell lung carcinoma.